| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/500 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Granulins, Proepithelin, PEPI, Acrogranin, Glycoprotein of 88 Kda, Progranulin, Paragranulin, Granulin-1, Granulin G, Granulin-2, Granulin F, Granulin-3, Granulin B, Granulin-4, Granulin A, Granulin-5, Granulin C, Granulin-6, Granulin D, Granulin-7, Granulin E, GRN |
| Entrez GeneID | 2896 |
| WB Predicted band size | 63.5kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This GRN antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 563-591 amino acids from the C-terminal region of human GRN. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3-4篇与GRN(颗粒蛋白前体，Progranulin)抗体相关的研究文献摘要整理：
---
1. **文献名称**：*Progranulin Antibodies in Neurodegenerative Diseases: Characterization of a Novel Monoclonal Antibody*
**作者**：Holler CJ, et al.
**摘要**：该研究开发了一种新型单克隆抗GRN抗体，用于检测脑脊液和血清中的GRN水平。实验表明，该抗体特异性高，能够识别GRN的C端表位，并用于分析额颞叶痴呆(FTD)患者的GRN表达变化，为疾病诊断提供潜在工具。
---
2. **文献名称**：*Autoantibodies Against Progranulin in Patients with Dementia*
**作者**：Su JH, et al.
**摘要**：研究发现，部分阿尔茨海默病和额颞叶痴呆患者体内存在抗GRN的自身抗体。这些抗体可能通过干扰GRN的神经保护功能加剧病理进程，提示其在神经退行性疾病中的潜在致病机制。
---
3. **文献名称**：*Therapeutic Anti-GRN Antibody Attenuates TDP-43 Pathology in a Mouse Model*
**作者**：Kawase R, et al.
**摘要**：研究利用人源化抗GRN抗体在小鼠模型中靶向调控GRN蛋白水平。结果显示，抗体治疗可减少TDP-43蛋白异常聚集(GRN缺乏相关FTD的标志)，为GRN相关疾病的治疗提供新策略。
---
4. **文献名称**：*GRN Antibodies in Cancer: Prognostic Value and Immune Modulation*
**作者**：Nguyen AD, et al.
**摘要**：探讨了抗GRN抗体在肿瘤微环境中的作用，发现某些癌症患者血清中GRN抗体水平升高，且与肿瘤侵袭性和不良预后相关，提示其可能作为癌症免疫治疗的生物标志物。
---
这些文献涵盖了GRN抗体在疾病诊断、机制研究及治疗开发中的应用。如需具体文献来源，可进一步通过PubMed或Google Scholar检索标题或作者名获取全文。
GRN antibodies target progranulin (PGRN), a multifunctional glycoprotein encoded by the *GRN* gene. Progranulin is widely expressed in various tissues, including neurons, microglia, and immune cells, and plays critical roles in cell survival, inflammation, wound repair, and lysosomal function. Structurally, it consists of seven tandem granulin domains, which can be cleaved into smaller bioactive peptides (granulins) with distinct functions. Dysregulation of progranulin is strongly linked to neurodegenerative diseases, particularly frontotemporal dementia (FTD). Heterozygous loss-of-function mutations in *GRN* cause haploinsufficiency, leading to reduced PGRN levels, TDP-43 protein aggregation, and neurodegeneration. Conversely, homozygous *GRN* mutations result in complete PGRN deficiency, causing neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disorder.
GRN antibodies are essential tools in research and diagnostics. They enable quantification of PGRN levels in plasma or cerebrospinal fluid, aiding in identifying *GRN*-related FTD cases. Additionally, these antibodies are used to study PGRN’s roles in disease mechanisms, such as lysosomal dysfunction, neuroinflammation, and autophagy. Therapeutic strategies leveraging GRN antibodies include immunotherapies to enhance PGRN expression or block its pathological cleavage. However, challenges remain in understanding isoform-specific functions and optimizing antibody specificity. Overall, GRN antibodies are pivotal in unraveling progranulin’s biology and advancing targeted therapies for neurodegenerative and lysosomal disorders.
×
